Human parainfluenza viruses medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
:::* 1.2 '''Creatinine clearance''' | :::* 1.2 '''Creatinine clearance''' | ||
::::* 30–50 mL/min: [[Ribavirin]] PO/IV maximal 200 mg q8h | ::::* 30–50 mL/min: [[Ribavirin]] PO/IV maximal 200 mg q8h | ||
::::* 10–30 mL/ min: No recommendation can be given | ::::* 10–30 mL/min: No recommendation can be given | ||
==References== | ==References== | ||
Revision as of 21:02, 28 July 2015
|
Human parainfluenza viruses Microchapters |
|
Differentiating Human parainfluenza viruses from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Human parainfluenza viruses medical therapy On the Web |
|
American Roentgen Ray Society Images of Human parainfluenza viruses medical therapy |
|
Directions to Hospitals Treating Human parainfluenza viruses |
|
Risk calculators and risk factors for Human parainfluenza viruses medical therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Antimicrobial regimen
- Parainfluenza virus[1]
- 1. Adults
- Preferred regimen: Ribavirin PO/IV 10 mg/kg q8h
- Day 1: Start with 600 mg loading dose THEN 200 mg q8h
- Day 2: 400 mg q8h
- Day 3: Increase the dose to a maximum of 10 mg/kg q8h
- 1.1 In case of adverse events
- Preferred regimen: Decrease dose or discontinue Ribavirin
- 1.2 Creatinine clearance
- 30–50 mL/min: Ribavirin PO/IV maximal 200 mg q8h
- 10–30 mL/min: No recommendation can be given
References
- ↑ Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P (2013). "Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus". Clin Infect Dis. 56 (2): 258–66. doi:10.1093/cid/cis844. PMC 3526251. PMID 23024295.